NCT05907980 - A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors | Biotech Hunter

Enrollment

219

Participants

Timeline

Start Date

May 24, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Solid Tumor

Interventions

DRUG

ROSE12

ROSE12 as a IV infusion

DRUG

Atezolizumab

Atezolizumab as a IV infusion

Trial Locations (4)

RECRUITING

NEXT Oncology, Fairfax

RECRUITING

MD Anderson Cancer Center, Houston

RECRUITING

National Cancer Center Hospital East, Kashiwa-shi

RECRUITING

National Cancer Center Hospital, Chuo-ku